# A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

> **NCT06847542** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 250 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DEVICE:** Susvimo PDS Implant
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT06847542
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2028-09-12
- **Final completion:** 2028-10-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847542, "A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06847542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*